EPRX Annual CFF
$15.56 M
+$7.26 M+87.46%
31 December 2023
Summary:
As of January 23, 2025, EPRX annual cash flow from financing activities is $15.56 million, with the most recent change of +$7.26 million (+87.46%) on December 31, 2023. During the last 3 years, it has risen by +$16.03 million (+3427.54%). EPRX annual CFF is now -60.91% below its all-time high of $39.81 million, reached on December 1, 2021.EPRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EPRX Quarterly CFF
-$4.60 M
-$101.90 K-2.26%
01 September 2024
Summary:
As of January 23, 2025, EPRX quarterly cash flow from financing activities is -$4.60 million, with the most recent change of -$101.90 thousand (-2.26%) on September 1, 2024. Over the past year, it has dropped by -$101.90 thousand (-2.26%). EPRX quarterly CFF is now -114.37% below its all-time high of $32.01 million, reached on March 1, 2021.EPRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EPRX TTM CFF
$13.99 M
-$20.89 M-59.88%
01 September 2024
Summary:
As of January 23, 2025, EPRX TTM cash flow from financing activities is $13.99 million, with the most recent change of -$20.89 million (-59.88%) on September 1, 2024. Over the past year, it has dropped by -$20.89 million (-59.88%). EPRX TTM CFF is now -68.18% below its all-time high of $43.97 million, reached on March 31, 2024.EPRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EPRX Cash From Financing Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +87.5% | -2.3% | -59.9% |
3 y3 years | +3427.5% | -4478.4% | -64.3% |
5 y5 years | +280.9% | -530.6% | +2017.8% |
EPRX Cash From Financing High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -60.9% | +87.5% | -119.9% | at low | -68.2% | +162.2% |
5 y | 5-year | -60.9% | +3427.5% | -114.4% | at low | -68.2% | +2017.8% |
alltime | all time | -60.9% | +3427.5% | -114.4% | at low | -68.2% | +2017.8% |
Eupraxia Pharmaceuticals Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | -$4.60 M(+2.3%) | $13.99 M(-59.9%) |
June 2024 | - | -$4.50 M(-119.4%) | $34.88 M(-20.7%) |
Mar 2024 | - | $23.15 M(<-9900.0%) | $43.97 M(+109.3%) |
Dec 2023 | $15.56 M(+87.5%) | -$59.00 K(-100.4%) | $21.01 M(-5.6%) |
Sept 2023 | - | $16.29 M(+254.8%) | $22.25 M(+316.9%) |
June 2023 | - | $4.59 M(+2259.1%) | $5.34 M(-51.6%) |
Mar 2023 | - | $194.60 K(-83.5%) | $11.03 M(+2.1%) |
Dec 2022 | $8.30 M | - | - |
Dec 2022 | - | $1.18 M(-287.9%) | $10.80 M(+13.4%) |
Sept 2022 | - | -$626.70 K(-106.1%) | $9.52 M(+1.9%) |
June 2022 | - | $10.29 M(<-9900.0%) | $9.34 M(+31.6%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | -$36.20 K(-64.0%) | $7.10 M(-81.9%) |
Dec 2021 | $39.81 M(-8612.5%) | -$100.50 K(-87.5%) | $39.15 M(+0.1%) |
Sept 2021 | - | -$805.00 K(-110.0%) | $39.10 M(-2.0%) |
June 2021 | - | $8.04 M(-74.9%) | $39.90 M(+23.7%) |
Mar 2021 | - | $32.01 M(<-9900.0%) | $32.25 M(-6664.1%) |
Dec 2020 | -$467.70 K(-108.4%) | -$149.40 K(+1892.0%) | -$491.30 K(+43.7%) |
Sept 2020 | - | -$7500.00(-101.9%) | -$341.90 K(+2.2%) |
June 2020 | - | $395.30 K(-154.2%) | -$334.40 K(-54.2%) |
Mar 2020 | - | -$729.70 K | -$729.70 K |
Dec 2019 | $5.57 M(+36.4%) | - | - |
Dec 2018 | $4.09 M(-44.1%) | - | - |
Dec 2017 | $7.30 M | - | - |
FAQ
- What is Eupraxia Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals annual CFF year-on-year change?
- What is Eupraxia Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals quarterly CFF year-on-year change?
- What is Eupraxia Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Eupraxia Pharmaceuticals?
- What is Eupraxia Pharmaceuticals TTM CFF year-on-year change?
What is Eupraxia Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of EPRX is $15.56 M
What is the all time high annual CFF for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high annual cash flow from financing activities is $39.81 M
What is Eupraxia Pharmaceuticals annual CFF year-on-year change?
Over the past year, EPRX annual cash flow from financing activities has changed by +$7.26 M (+87.46%)
What is Eupraxia Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of EPRX is -$4.60 M
What is the all time high quarterly CFF for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high quarterly cash flow from financing activities is $32.01 M
What is Eupraxia Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, EPRX quarterly cash flow from financing activities has changed by -$101.90 K (-2.26%)
What is Eupraxia Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of EPRX is $13.99 M
What is the all time high TTM CFF for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals all-time high TTM cash flow from financing activities is $43.97 M
What is Eupraxia Pharmaceuticals TTM CFF year-on-year change?
Over the past year, EPRX TTM cash flow from financing activities has changed by -$20.89 M (-59.88%)